Home » Stocks » INZY

Inozyme Pharma, Inc. (INZY)

Stock Price: $20.21 USD 0.21 (1.05%)
Updated Mar 1, 2021 1:47 PM EST - Market open
Market Cap 467.46M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 18.10M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 1
Last Price $20.21
Previous Close $20.00
Change ($) 0.21
Change (%) 1.05%
Day's Open 20.31
Day's Range 19.90 - 21.85
Day's Volume 29,853
52-Week Range 16.10 - 31.65


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 3 weeks ago

BOSTON, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of ab...

GlobeNewsWire - 1 month ago

– U.S. Food and Drug Administration cleared Investigational New Drug Application –

GlobeNewsWire - 3 months ago

–  Submitted CTA for INZ-701 for the treatment of ENPP1 deficiency to United Kingdom regulatory agency –

GlobeNewsWire - 3 months ago

Dr. Johnson Brings More Than 25 Years of Experience in Developing and Implementing Global Regulatory and Clinical Development Strategies from Preclinical Through Product Approval Dr. Johnson B...

GlobeNewsWire - 4 months ago

– Dr. Sabbagh Brings More Than 20 Years of Experience in Rare Genetic Disorders and Mineral Metabolism Research Development Programs –

GlobeNewsWire - 5 months ago

Upsized IPO in July 2020 raised $128.8 million in gross proceeds

About INZY

Inozyme Pharma, a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as in the early stages of development for calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is... [Read more...]

IPO Date
Jul 24, 2020
Axel Bolte
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Inozyme Pharma stock is "Strong Buy." The 12-month stock price forecast is 36.67, which is an increase of 81.44% from the latest price.

Price Target
(81.44% upside)
Analyst Consensus: Strong Buy